Printer Friendly
The Free Library
4,474,505 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Teva Received Final Approval for Doxazosin Mesylate to be Shipped Immediately.


Business/Health Editors

JERUSALEM--(BUSINESS WIRE)--Oct. 22, 2000

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has received from the U.S. FDA final approval to manufacture and market Doxazosin doxazosin /dox·a·zo·sin/ (dok-sa´zo-sin) a compound that blocks a; used as d. mesylate mesylate /mes·y·late/ (mes´i-lat) USAN contraction for methanesulfonate.

mes·y·late (ms
in the treatment of hypertension and of benign prostatic hyperplasia.
 Mesylate 1, 2, 4 and 8 mg Tablets.

Doxazosin Mesylate dox·a·zo·sin mesylate (dk-sz-s is the generic version of Pfizer's cardiovascular/benign prostatic hyperplasia drug - Cardura Car·dur·a (kär-dr)
A trademark for the drug doxazosin mesylate.
(R). Combined 1999 branded sales were approximately $320 million.

Teva received the final approval upon the expiration of the patent on the branded product and will ship the product immediately. Other companies have received similar approvals.

Teva Pharmaceutical Industries Ltd. headquartered in Israel is among the top 50 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. Over 85% of Teva's sales are outside Israel, mainly in North America and Europe. The Company develops, manufactures and markets generic and branded human pharmaceuticals and active pharmaceutical ingredients.

Safe Harbor Statement: This report contains forward-looking statements, which express the beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward looking statements. Important factors that could cause or contribute to such differences include the impact of pharmaceutical industry regulation, the difficulty of predicting FDA and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, acceptance and demand for new pharmaceutical products and new therapies, the impact of competitive products and pricing, the availability and pricing of ingredients used in the manufacture of pharmaceutical products, uncertainties regarding market acceptance of innovative products newly launched, currently being sold or in development, the impact of restructuring of clients, reliance on strategic alliances, fluctuations in currency, exchange and interest rates, operating results, the impact of the year 2000 issue and other factors that are discussed in the Company's Annual Report on Form 20-F and the Company's other filings with the U.S. Securities and Exchange Commission.
COPYRIGHT 2000 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:7ISRA
Date:Oct 22, 2000
Words:344
Previous Article:REMINDER/Concero To Announce 3Q Results.
Next Article:Elections Canada: Canadians Abroad Can Vote in General Election.
Topics:



Related Articles
IVAX Receives Tentative Approval for Doxazosin Mesylate Tablets.
IVAX Receives Final Approval for Doxazosin Mesylate Tablets.
Faulding receives final FDA approval for doxazosin tablets.
Mylan Receives Approval on Doxazosin Mesylate Tablets.
Teva Earnings Per Share for Q3 2000 Rise 26%; Copaxone Sales Rise 59%.
FDA APPROVES BIOVAIL'S GENERIC PROCARDIA XL 30MG DOSAGE.
HYTRIN OUTPERFORMS PROSCAR IN PROSTATE MEDICINE STUDY.(BUSINESS)
Chemical products.(Brochures)
Cardiovascular Safety of Vardenafil and Alpha-Blockers Combined: Subgroup Analysis of a Post-Marketing Study.(Section II: Clinical...
FDA APPROVES TEVA'S ANDA TO MARKET GENERIC VERSION OF ZOCOR.

Terms of use | Copyright © 2008 Farlex, Inc. | Feedback | For webmasters | Submit articles